First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, ...

IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...

GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed ...

In the past 60 days, estimates for Krystal Biotech’s 2024 EPS have increased from $2.09 to $2.38. The consensus estimate for 2025 earnings has improved from $4.33 to $7.31. Year to date, shares of ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

A group of lawmakers wants the U.S. Patent & Trademark Office and drug companies to change their approach toward handling ...

GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for ...

The pioneering DNA testing firm has been struggling to stay afloat financially despite ambitious ventures to provide health ...

This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...

Ginkgo Bioworks , which is building the leading platform for cell programming and biosecurity, proudly announces the launch ...

A separate US-based single-arm OLIKOS Phase IIIb study showed that at 12 months, all clinically stable RMS patients who switched from intravenous (IV) anti-CD20 therapy to Kesimpta showed no new ...